2023
Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
Clark E, Perin J, Herrmann N, Brawman‐Mintzer O, Lanctôt K, Lerner A, Mintzer J, Padala P, Rosenberg P, Sami S, Shade D, van Dyck C, Porsteinsson A, Group F. Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023, 9: e12403. PMID: 37538343, PMCID: PMC10394740, DOI: 10.1002/trc2.12403.Peer-Reviewed Original ResearchNeuropsychiatric symptomsEffects of methylphenidateAlzheimer's diseaseSecondary analysisNeuropsychiatric Inventory scoresElation/euphoriaSymptoms of apathyIndividual neuropsychiatric symptomsPresentation of symptomsImpact of methylphenidateIndividual domain scoresAppetite/Catecholaminergic dysfunctionMonth 6Neuropsychiatric InventoryCaregiver scoresNPI domainsNew symptomsTreatment periodDomain scoresMeaningful improvementsMethylphenidateSymptomsPlaceboDisease
2020
Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate
van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanctôt KL, Rosenberg PB. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. American Journal Of Geriatric Psychiatry 2020, 29: 51-62. PMID: 32461027, PMCID: PMC7641967, DOI: 10.1016/j.jagp.2020.04.026.Peer-Reviewed Original ResearchConceptsTreatment of apathyAlzheimer's diseaseCortical-basal ganglia circuitsPrefrontal cortexMotivated behaviorPublic health burdenSymptoms of apathyCatecholaminergic treatmentNeurobiologic rationaleNeuropsychiatric symptomsDopamine actionGanglia circuitsHealth burdenThalamocortical circuitsCognitive symptomsMethylphenidate actionsCatecholamine actionNeuronal circuitsSymptomsDiseaseApathetic behaviorTreatmentInitial trialMethylphenidateAD results
2009
Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET
Santhosh L, Estok KM, Vogel RS, Tamagnan GD, Baldwin RM, Mitsis EM, MacAvoy MG, Staley JK, van Dyck CH. Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET. Psychiatry Research 2009, 173: 212-217. PMID: 19682865, DOI: 10.1016/j.pscychresns.2009.03.007.Peer-Reviewed Original ResearchConceptsPositron emission tomographyAD patient samplesAlzheimer's diseaseAD patientsAnterior cingulateBehavioral symptomsBrain serotonin 2A (5-HT(2A)) receptorsPatient samplesConstant infusion paradigmSerotonin 2A receptorProbable Alzheimer's diseaseMajor behavioral symptomsBehavioral correlatesInfusion paradigmPostmortem studiesPsychotic symptomsElderly controlsMRI scansSubcortical regionsSerotonergic dysregulationEmission tomographyPatientsDiseaseInterest analysisSymptoms
2006
Apolipoprotein E ɛ4 Allele Increases Risk for Psychotic Symptoms in Alzheimer's Disease
Zdanys KF, Kleiman TG, MacAvoy MG, Black BT, Rightmer TE, Grey M, Garman KS, Tampi RR, Gelernter J, van Dyck CH. Apolipoprotein E ɛ4 Allele Increases Risk for Psychotic Symptoms in Alzheimer's Disease. Neuropsychopharmacology 2006, 32: 171-179. PMID: 16841077, DOI: 10.1038/sj.npp.1301148.Peer-Reviewed Original ResearchConceptsAD patientsPsychotic symptomsAlzheimer's diseaseBehavioral symptomsNeuropsychiatric InventoryApolipoprotein EMultiple logistic regression modelSporadic Alzheimer's diseaseGenetic risk factorsSevere-stage Alzheimer's diseaseLogistic regression modelsDifferent risk profilesDementia progressesRisk factorsIncrease riskBehavioral disturbancesPatientsDisease severitySymptomsSignificant psychosisRisk profileGreater riskApoEExploratory analysisDisease